The anti-CTLA-4 drugs (including Ipilimumab) and anti-PD-1 drugs (including Nivolumab and Pembrolizumab) have therapeutic effects in advanced metastatic melanoma and are used as adjuvant therapy after surgery (19). This evidence concerns the gene CTLA4 and metastatic melanoma.